Quality-of-life scores improve after 96 weeks of PEG-IFNa-2a treatment of hepatitis D: An analysis of the HIDIT-II trial

Basit Öğe Kaydı
dc.contributor.authorDinkelborg, Katja
dc.contributor.authorKahlhöfer, Julia
dc.contributor.authorDörge, Petra
dc.contributor.authorYurdaydın, Cihan
dc.contributor.authorHardtke, Svenja
dc.contributor.authorCaruntu, Florin Alexandru
dc.contributor.authorCurescu, Manuela Gabriela
dc.contributor.authorYalçın, Kendal
dc.date.accessioned2024-04-24T17:11:48Z
dc.date.available2024-04-24T17:11:48Z
dc.date.issued2023
dc.departmentDicle Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalıen_US
dc.description.abstractBackground & AimsInfection with the hepatitis D virus (HDV) causes the most severe form of viral hepatitis with a high risk to develop clinical complications of liver disease. In addition, hepatitis delta has been shown to be associated with worse patient-reported outcomes. Until recently, only pegylated interferon alfa could be used to treat hepatitis delta. MethodsHere, we investigated quality of life (QOL) as assessed by the Short Form 36 Health Survey (SF-36) in patients undergoing antiviral therapy with pegylated interferon alfa (PEG-IFNa-2a)-based treatment in the HIDIT-II trial. HIDIT-II was a randomized prospective trial exploring PEG-IFNa-2a with tenofovir disoproxil (TDF) or placebo for 96 weeks in patients with compensated hepatitis delta. Surveys completed by 83 study participants before, during, and after treatments were available. ResultsOverall, we observed a reduced QOL of HDV patients compared with a reference population, both in physical as well as mental scores. Interestingly, PEG-IFNa-2a treatment showed only minor impairment of the QOL during therapy. Moreover, HDV-RNA clearance was not associated with relevant changes in physical or social SF-36 scores, whereas an improvement of fibrosis during treatment was associated with increased QOL. Overall, slight improvements of the QOL scores were observed 24 weeks after the end of treatment as compared with baseline. TDF co-treatment had no influence on QOL. ConclusionsOverall, our findings suggest that PEG-IFNa-2a was reasonably tolerated even over a period of 96 weeks by hepatitis D patients reporting SF-36 questionnaires. Of note, several patients may benefit from PEG-IFNa-2a-based therapies with off-treatment improvements in quality of life.en_US
dc.identifier.citationDinkelborg, K., Kahlhöfer, J., Dörge, P., Yurdaydın, C., Hardtke, S., Caruntu, F. A. ve diğerleri. (2023). Quality-of-life scores improve after 96 weeks of PEG-IFNa-2a treatment of hepatitis D: An analysis of the HIDIT-II trial. Liver International, 43(8), 1663-1676.
dc.identifier.doi10.1111/liv.15602
dc.identifier.endpage1676en_US
dc.identifier.issn1478-3223
dc.identifier.issn1478-3231
dc.identifier.issue8en_US
dc.identifier.pmid37183524
dc.identifier.scopus2-s2.0-85159194675
dc.identifier.scopusqualityQ1
dc.identifier.startpage1663en_US
dc.identifier.urihttps://doi.org/10.1111/liv.15602
dc.identifier.urihttps://hdl.handle.net/11468/17725
dc.identifier.volume43en_US
dc.identifier.wosWOS:000999103300001
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.ispartofLiver International
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectHepatitis Den_US
dc.subjectInterferon-based therapyen_US
dc.subjectQuality of lifeen_US
dc.subjectSf36en_US
dc.titleQuality-of-life scores improve after 96 weeks of PEG-IFNa-2a treatment of hepatitis D: An analysis of the HIDIT-II trialen_US
dc.titleQuality-of-life scores improve after 96 weeks of PEG-IFNa-2a treatment of hepatitis D: An analysis of the HIDIT-II trial
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Quality-of-life scores improve after 96 weeks of PEG-IFNa-2a treatment of hepatitis D An analysis of the HIDIT-II trial.pdf
Boyut:
2.43 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Makale Dosyası
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu